

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	<b>CRESO PHARMA LIMITED</b>
<b>ABN</b>	<b>89 609 406 911</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Adam Blumenthal
<b>Date of last notice</b>	19 February 2020

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct & Indirect
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	<ul style="list-style-type: none"> <li>- Anglo Australasia Holdings Pty Ltd &lt;Anglo Australasia A/C&gt;</li> <li>- Atlantic Capital Holdings Pty &lt;Atlantic Capital A/C&gt;</li> </ul> <p>Both of the above entities are director-related entities.</p>
<b>Date of change</b>	2 June 2020
<b>No. of securities held prior to change</b>	<p><b>Direct:</b> <b>Adam Blumenthal:</b></p> <ul style="list-style-type: none"> <li>- 1 Fully Paid Ordinary Share</li> </ul> <p><b>Indirect:</b> <b>Anglo Australasia Holdings Pty Ltd &lt;Anglo Australasia A/C&gt;:</b></p> <ul style="list-style-type: none"> <li>- 6,250,000 Fully Paid Ordinary Shares</li> <li>- 2,750,000 Listed CPHO Options (\$0.80, 21 August 2020)</li> </ul> <p><b>Atlantic Capital Holdings Pty &lt;Atlantic Capital A/C&gt;:</b></p> <ul style="list-style-type: none"> <li>- 1,958,387 Fully Paid Ordinary Shares</li> <li>- 2,128,387 CPHOPT20 Options (\$0.35, 12 Feb 2023)</li> </ul>

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>Class</b>	<ul style="list-style-type: none"> <li>- CPHOPT29 Options (\$0.25, 2 Jun 2023)</li> <li>- CPHOPT31 Options (\$0.20, 2 Jun 2023)</li> </ul>
<b>Number acquired</b>	<ul style="list-style-type: none"> <li>- 4,000,000 CPHOPT29 Options (\$0.25, 2 Jun 2023)</li> <li>- 8,000,000 CPHOPT31 Options (\$0.20, 2 Jun 2023)</li> </ul>
<b>Number disposed</b>	N/A
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	Nil
<b>No. of securities held after change</b>	<p><b><u>Direct:</u></b>  <b>Adam Blumenthal:</b></p> <ul style="list-style-type: none"> <li>- 1 Fully Paid Ordinary Share</li> </ul> <p><b><u>Indirect:</u></b>  <b>Anglo Australasia Holdings Pty Ltd &lt;Anglo Australasia A/C&gt;:</b></p> <ul style="list-style-type: none"> <li>- 6,250,000 Fully Paid Ordinary Shares</li> <li>- 2,750,000 Listed CPHO Options (\$0.80, 21 August 2020)</li> </ul> <p><b>Atlantic Capital Holdings Pty &lt;Atlantic Capital A/C&gt;:</b></p> <ul style="list-style-type: none"> <li>- 1,958,387 Fully Paid Ordinary Shares</li> <li>- 2,128,387 CPHOPT20 Options (\$0.35, 12 Feb 2023)</li> <li>- 4,000,000 CPHOPT29 Options (\$0.25, 2 Jun 2023)</li> <li>- 8,000,000 CPHOPT31 Options (\$0.20, 2 Jun 2023)</li> </ul>
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	<p>Atlantic Capital Holdings Pty &lt;Atlantic Capital A/C&gt;, as nominee for EverBlu Capital Pty Ltd ("<b>Everblu</b>"), received 4,000,000 CPHOPT29 Options (\$0.25, 2 Jun 2023) and 8,000,000 CPHOPT31 Options (\$0.20, 2 Jun 2023), as a part allocation for services provided by Everblu in respect of the New Convertible Note Facility and Corporate Advisory.</p> <p>Refer to the Prospectus dated 2 June 2020 for further details.</p>

+ See chapter 19 for defined terms.

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
<b>Interest after change</b>	N/A

**Part 3 – <sup>+</sup>Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

---

<sup>+</sup> See chapter 19 for defined terms.